Is white matter involved in patients entered into typical trials of neuroprotection?

Stroke

Volumn 36, Issue 12, 2005, Pages 2742-2744

  Ho, Prahlad W ^a   Reutens, David C ^a   Phan, Thanh G ^a   Wright, Peter M ^a   Markus, Romesh ^a   Indra, Indra ^a   Young, Dennis ^a   Donnan, Geoffrey A ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Imaging; Ischemia; Neuroprotective agents

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN SIZE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GRAY MATTER; HUMAN; MALE; NEUROIMAGING; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STROKE; WHITE MATTER; BRAIN MAPPING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; MIDDLE AGED; MYELIN SHEATH; ORGAN SIZE; PATHOLOGY; RADIOGRAPHY; REFERENCE VALUE;

NEUROPROTECTIVE AGENT;

AGED; AGED, 80 AND OVER; BRAIN MAPPING; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYELIN SHEATH; NEUROPROTECTIVE AGENTS; ORGAN SIZE; REFERENCE VALUES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33644698763     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000189748.52500.a7     Document Type: Article

References (10)

1. STAIR. Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug Developement. Stroke. 1999;30:2752-2758.
2. Muir KW, Lees KR, Ford I, Davis S. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet. 2004;363:439-445.
3. Siesjo B. Pathophysiology and treatment of focal ischaemia Part 2: Mechanisms of damage and treatment. J Neurosurg. 1992;77:337-354.
4. Yoshioka A, Hardy M, Younkin DP, Grinspan JB, Stem JL, Peasure D. Alpha-amino-3-hydroxy-5methyl-4-isoazoleproprionate(AMPA) receptors mediate excitotoxicity in the oligodendroctye lineage. J Neurosci. 1995;64:2442-2448.
5. Zhang K, Sejnowski T. A universal scaling law between gray matter and white matter of cerebral cortex. Proc Nat Acad Sci U S A. 2000;97:5621-5626.
6. Krams M, Lees K, Hacke W, Grieve A, Orgogozo J, Ford G; for Astin Study Investigators. Acute stroke therapy by inhibition of neutrophils (ASTIN): an adaptive dose-response study of uk-279,276 in acute ischemic stroke. Stroke. 2003;34:2543-2548.
7. Post 010 and Post 011: Potassium Opening Stroke Trial. The Internet Stroke Centre. Available at: http://www.strokecenter.org/trials. Accessed March 20, 2003.
8. Lees K, Asplund K, Carolei A, Davis S, Deiner HC, Kaste M, Orgogozo JM, Whitehead J. Glycine antagonists (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. Lancet. 2000;355:1949-1954.
9. Woods R, Grafton S. Automated image registration 1: General methods and intrasubject, intramodality validation. J Comp Assist Tomograph. 1998;22:139-152.
10. Fiblast Phase 3: Trafermin in Acute Ischemic Stroke. The Internet Stroke Centre. Available at: http://www.strokecenter.org/trials. Accessed March 20, 2003.